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Programmed cell death 1 receptor 
A B S T R A C T   
Immune checkpoint inhibitory (ICI) therapy represents a novel approach in a variety of cancers, with impressive 
survival benefit. With ICIs, however, a new spectrum of immune related adverse events (irAE) including life 
threatening hypohysitis has emerged. This autopsy study aimed to investigate inflammatory cells, PD-1 and PD- 
L1 expression in cases of patients who developed hypophysitis and involvement of other organs. 
We analysed 6 patients, who were treated with ICIs and developed hypophysitis. Two received an additional 
MAP-kinase inhibitor, MEK-inhibitor and cytotoxic chemotherapy. Besides the pituitary gland, all investigated 
adrenal glands (5/5) were affected; three cases had other organs involved (liver (2/6), thyroid (2/6), lung (1/6), 
myocardium (1/6), colon (1/6). The inflammatory cells of involved organs were further specified and PD1 and 
PDL-1 expression was analyzed using immunohistochemistry. We observed that patients treated with ICIs alone 
showed T-cell predominant lymphocytic infiltrates, whereas patients receiving additional therapies demon-
strated an increase in B- and T-lymphocytes. Surprisingly, the dominant inflammatory population was not T-cell, 
but type 2 macrophages. CD25 positive T-regs were sparse or absent. 
Our study suggests that T cell activation is only partially responsible for irAE. ICI therapy interaction with 
CTLA-4, PD-1 and PDL-1 in type 2 macrophages appears to result in disturbance of their control. Furthermore, 
depletion of T-regs seems to contribute significantly. Our findings with simultaneous pituitary and adrenal gland 
involvement underlines the systemic involvement as well as the importance of monitoring cortisol levels to avoid 
potentially life threatening hypocortisolism.   
1. Introduction 
Treatment with immune checkpoint inhibitors (ICIs) has revolu-
tionized the approach to cancer therapy. In contrast to previous thera-
pies, which are directly toxic to cancer cells, ICIs activate the patient’s 
immune system by inhibiting T-cell inactivation (Buchbinder and Hodi, 
2015). The tremendous survival benefit of ICIs as first line treatment was 
first shown for metastatic melanoma (Larkin et al., 2015a). 
Currently, monoclonal antibodies against two different pathways of 
T-cell inactivation are FDA and EMA approved. One medication class 
comprising Ipilimumab and Tremelimumab inhibits the cytotoxic T-cell 
lymphocyte antigen-4 (CTLA-4) pathway. Another class, which includes 
Nivolumab and Pembrolizumab, inhibits the program death-1 receptor 
(PD-1) or its ligand (PD-L1) with Durvalumab and Atezolizumab (Robert 
et al., 2015; Borghaei et al., 2015). 
ICI therapy has demonstrated impressive results in a variety of solid 
tumors and haematologic malignancies (Larkin et al., 2015b; Motzer 
et al., 2015; Brahmer et al., 2015; Rosenberg et al., 2016; Reck et al., 
2016; Kaufman et al., 2016; Ferris et al., 2018; Jelinek et al., 2017). At 
present, published data underline the long-time survival benefit in 
melanoma patients, who have undergone combination therapy simul-
taneously targeting CTLA-4 and PD-1 pathways (Larkin et al., 2019, 
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2015b). 
However, a novel spectrum of autoimmune–inflammatory toxicities 
has emerged with ICI therapy, which differ from those classically 
encountered with chemotherapy or other forms of immunotherapy 
(Abdel-Wahab et al., 2016; De Velasco et al., 2017). 
The severity and frequency of immune related adverse events (irAEs) 
are dose dependent (Kaehler et al., 2010). Hypophysitis has emerged as 
a potentially life threatening adverse event, carries a variable incidence 
(0–17 %). Prior to therapies with ICIs, hypophysitis was an exceptionally 
rare adverse event in patients treated with interferon for viral hepatitis 
(Caturegli et al., 2005). The pathogenic mechanism of these new adverse 
events is postulated to be immune related (Sanderson et al., 2005; 
Iwama et al., 2014). 
In the present study, we have analysed the histopathology of irAEs in 
six autopsy-examined patients treated with Ipilimumab alone or in 
combination with Nivolumab or Pembrolizumab. In all cases, we 
observed involvement of more than one organ, indicating the systemic 
nature of irAEs. Besides the pituitary gland, all investigated adrenal 
glands (5/5) were affected. Other involved organs included the colon 
(2/6), lungs (1/6), thyroid (2/6), liver (2/6) and heart (1/6). 
Based on the observation that ICIs predominantly activate T-lym-
phocytes, the assumption could be made that T cell infiltrates would be 
more prevalent in irAE. Interestingly, macrophages type 2 (M2) domi-
nate the inflammatory infiltrates and are accompanied by T-reg deple-
tion. These observations suggest that the interaction with CTLA-4, PD-1 
and PDL-1 in M2 and T-regs contributes to irAE. 
2. Material and methods 
This autopsy study was approved by the Ethics Committee of the 
Canton Zurich (BASEC-Nr. PB 2017−27). The institution’s autopsy re-
cords were retrospectively searched from 2019−2011 for patients with 
hypophysitis and metastatic melanoma, who had been treated with ICIs. 
Corresponding medical records were reviewed for clinical history, and 
autopsy findings. 
In all cases, autopsy tissue was fixed in 4% buffered formalin, 
routinely processed and embedded in paraffin. Subsequently, 2–4 μm 
thick sections were stained with hematoxylin and eosin and elastica van 
Gieson. For additional postmortem studies, paraffin-embedded sections 
of pituitary, adrenal gland, thyroid, myocardium, lung, and liver were 
immunostained with commercially available antibodies for immune 
cells (Table 1). Additionally, an in vivo colon biopsy of patient 3 was 
investigated. Scoring of the inflammatory cells was evaluated semi- 
quantitatively based on an arbitrary five-tiered scale from negative to 
4+: 0 was recorded, if staining was completely absent or fewer than 1% 
of inflammatory cells were immunopositive, 1+ corresponded to 1–5 % 
of inflammatory cells, 2+ for 6–25 %, 3+ for 26–50 % and 4+ for over 
50 % of inflammatory cells. For PD-1 and PD-L1, plasma membrane 
staining of any intensity was considered positive. Diffuse cytoplasmic 
staining in parenchymal cells was not counted. Granular positivity in 
macrophages of PD-L1 was regarded as positive. PD-1 and PD-L1 was 
scored separately in parenchymal and inflammatory cells using the 
semiquantitative Roche algorithm for tumors: - absence, 1+ positivity in 
<1%, 2+ positivity in 1 %–4 %, 3+ positivity in 5 %–50 % of paren-
chymal cells. For inflammatory cells, 3+ corresponds to 5 %–9 % posi-
tivity and 4+ for positivity in over 9% of inflammatory cells. 
Appropriate positive and negative controls were used. 
3. Results 
3.1. Clinics 
3.1.1. Patient 1 
A 57-year-old female was diagnosed with nevoid melanoma of the 
thigh with Breslow thickness 1.5 mm. A sentinel lymph node biopsy was 
negative. Three years later, she developed three in-transit metastases 
and a single brain metastasis. Therapy was started with four cycles of 
Ipilimumab followed by postoperative radiotherapy with 30 gy 
(Table 2).The patient suffered a possible immunotherapy related skin 
rash and thyroiditis. MRI demonstrated no signs of hypophysitis. Two 
weeks before death, the patient received a single infusion of Pem-
brolizumab. Post mortem ACTH and cortisol values were extremely low 
with 15 ng/l and 4 nmol/l, respectively (Table 3). 
3.1.2. Patient 2 
A 81 year-old female was diagnosed with uveal melanoma and un-
derwent local proton beam therapy. Three years later, she developed 
multiple liver metastases and was treated with selective intra-arterial 
radiotherapy followed by Ipilimumab and Nivolumab (Table 2). Five 
weeks after ICI medication, she became comatose and died. 
3.1.3. Patient 3 
A 64-year-old male was diagnosed with melanoma of the left chest, 
SSM-type, Breslow thickness 1.5 mm Clark level IV with a single axillary 
lymph node metastasis. Three years after initial diagnosis, he developed 
a single brain metastasis. Postoperatively, the patient received radio-
therapy and three cycles of Ipilimumab (Table 2). After the third cycle, 
he developed immune therapy-associated, histologically confirmed co-
litis and MRI evidence of hypophysitis. Prednisone, 50 mg per day, was 
started and continued for 5 weeks. One month after prednisone therapy 
was discontinued, the patient was hospitalized with mental status 
changes. The ACTH level was with 15 ng/l low (no: >46 ng/l) and 
Table 1 
Details of immunohistochemical antibodies.  
Antibody Clone Dilution Source Platform 
CD3 LN10 1:500 Leica Ventana 
CD4 SP35 Ventana-Roche Prediluted Ventana 
CD8 C8/144B DAKO A/S 1:100 Ventana 
CD20 L26 Ventana-Roche Prediluted Ventana 
CD25 4C9 Cell Marque 1:100 Bond/Leica 
CD68 PG-M1 DAKO A/S 1:50 Ventana 
CD163 163C01 / 10D6 NeoMarkers 1:200 Bond/Leica 
PD-1 J116 DAKO A/S 1:50 Ventana 
PDL1 263 SP263 Ventana-Roche Prediluted Ventana 
MPO polycloncal NeoMarkers 1:200 Ventana  
Table 2 
Therapy.   
Medication FM LM RT 
1 Ipilimumab 24 16 Brain Nivolumab 1  26 
2 Ipilimumab + Nivolumab 5 1 PB 36   SIRT 7  
3 Ipilimumab 23 9 Brain 27 
4 Ipilimumab 7 4 LN 28 
5 Ipilimumab 56 53 Brain 8  
Pembrolizumab 52 40   
Tafinar + Mekinist 40 36   
Zellboraf + Cotellic 32 2   
Temodal 2   
6 Ipilimumab 109 101 LN 9  
Dabrafenib+ 48 17   
Trametinnib+
Spartalizumab     
Vindesine+ 16 14   
Cisplatin     
Encorafenib+ 7    
Binimetinib    
FM First medication before death in weeks; LM Last medication before death in 
weeks; RT Radiotherapy before death in weeks; PB Proton beam; LN Lymph 
nodes; SIRT selective intraarterial radiotherapy before death in weeks. 
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cortisol only 72 mmol/l, (normal range: 64–327). Due to rapid general 
deterioration, further diagnostic steps were not undertaken and the 
patient died. 
3.1.4. Patient 4 
A 63-year-old male was diagnosed with cutaneous melanoma on the 
neck, SSM-type, Breslow thickness 0.7 mm, Clark level IV. Neck 
dissection demonstrated positive lymph nodes. Five months after 
radiotherapy, pulmonary metastatic spread was observed and the pa-
tient received two cycles of Ipilimumab. After the second cycle, the 
patient was hospitalized with severe colitis and hyponatremia. ACTH 
(1200 ng/l) and cortisol (1300 nmol/l) levels were elevated. Cranial 
MRI showed no signs of hypophysitis. Two weeks after hospitalization, 
the patient died (Table 2 and 3). 
3.1.5. Patient 5 
A 44-year-old female was diagnosed with anal melanoma, Breslow 
thickness 5 mm. Left inguinal sentinel lymph node biopsy was positive. 
Inguinal lymphadenectomy demonstrated a second, partially extranodal 
metastasis, which prompted postoperative radiotherapy. After months, 
local anal recurrence was detected as well as subcutaneous inguinal and 
presacral metastases. Ipilimumab therapy was started. After 2 cycles of 
Ipilimumab, inguinal tumor progression was noted and Pembrolizumab 
therapy was started. Subsequently, the patient developed autoimmune 
thyroiditis and therefore received Euthyrox. Despite one infusion of 
Pembrolizumab, a thoracic vertebral body metastasis developed. Ther-
apy was switched to MEK inhibitors, including Tafinar and Mekinist, 
which triggered an auto-inflammatory syndrome with SIRS and MODS. 
Therefore, combination therapy including Zelboraf and Cotellic was 
started. However, cerebral metastases were detected. Whole brain 
irradiation and operation were performed. Five weeks before death, 
therapy was changed to Temodal (Table 2). 
3.1.6. Patient 6 
A 34-year-old male was diagnosed with melanoma on the right chest, 
nodular type with Breslow thickness 3.4 mm and lymph node metasta-
ses. Despite 4 cycles of Ipilimumab, there was tumor progression with 
thoracic metastases. The patient developed irAEs with hypophysitis and 
colitis after 11 weeks of therapy. ACTH and cortisol levels were low with 
21 ng/ml and 79 mmol/l, respectively (Table 3). Glucocorticoid therapy 
with 2 × 4 mg dexamethasone per day was started and then changed to 
prednisone. Fifteen weeks after initial therapy, he received 30 mg hy-
drocortisone per day. Hydrocortisone was gradually stopped after 8 
weeks. 
Six month later, the patient developed paraaortic lymph node me-
tastases. Therapy with Dabrafenib, Tramatinib and Spartalizumab was 
started; however, progressive disease developed. Combination therapy 
was stopped and the patient underwent percutaneous radiotherapy with 
13 × 3 Gy. In addition, he received two infusions of Anti PD-1 and LAG. 
The disease progressed relentlessly with evidence of lung and bone 
metastases. A single cycle of XGEVA was administered in combination 
with BRAFTOVI and MEKTOVI (Table 2). Tumor progression continued 
with death ensuing 31 month after initial diagnosis. 
3.2. Autopsy findings 
3.2.1. Macroscopy 
Patient 4 and 6 demonstrated extensive metastatic disease involving 
the lymph nodes, lung, liver, kidney, bones, mediastinum and heart. 
Patient 2 had liver and bone and patient 5 only brain metastases. No 
residual tumor was found in patients 1 and 3 (Table 3). 
3.2.2. Histopathology 
All patients had inflammation of the pituitary gland. Additionally, all 
investigated adrenal glands (5/5) were also inflamed. In patient 1, 
thyroiditis, myocarditis, pneumonitis and hepatitis was seen and in 
patient 5, thyroiditis and hepatitis. 
3.2.3. Adrenal and pituitary gland of patient 1−6 
Investigated adrenal glands demonstrated macrophage predominant 
inflammation and mild fibrosis were observed. Specifically, type 2 
macrophages with co-expression of CD68 and CD163 comprised over 50 
% of inflammatory cells. The infiltrate was accompanied by 26 %–50 % 
T-lymphocytes with equally distributed positivity for CD4 and CD8 in 2 
patients, whereas one patient showed a slight CD4 and another slight 
CD8 predominance. With the exception of patient 5, who received 
additional to immune check point inhibitors kinase inhibitors, B-lym-
phocytes were absent or less than 5% percent. CD25 positive T-regs were 
found in less than 1% of all investigated adrenal glands. Few to mod-
erate PD-L1 positivity was found in macrophages in 3 cases and in the 
parenchymal cells of 2 patients (Fig. 1a A–L; Table 4). 
Five of 6 pituitary glands showed a M2 rich inflammation accom-
panied by few to moderate lymphocytes. Patient 3 showed pronounced 
atrophy and fibrosis. B- and T- lymphocytes were roughly equally 
distributed or fewer in 4 of 5 patients (Fig. 1b A–J; Fig. 1c E–H). Only 
patient 6, who received additional kinase inhibitors and cytotoxic 
chemotherapy, demonstrated a B-cell predominance over T-cells. CD25 
was present in single cells in 4 of 5 patients. Parenchymal PD-L1 posi-
tivity was found in 5/5 pituitary glands. Three patients showed 5 %–50 
% positivity in parenchymal cells and 2 in less than 1%. Four of 5 pa-
tients had less than 1% PD-L1 positive macrophages (Fig. 1b K and L). 
PD-1 was negative in parenchymal and inflammatory cells, with the 
exception of patient 3 with 1 %–4 % positivity of inflammatory cells. The 
anterior pituitary gland of patient 4 showed acute necrosis with gran-
ulocytic reaction in with macrophage rich inflammation (Fig. 1c A–D). 
There were only occasional CD4 or CD8 positive lymphocytes. Unfor-
tunately, there was insufficient material to perform staining for CD163, 
CD20, CD25, PD-1 or PD-L1, 
3.2.4. Thyroid gland of patients 1 and 5 
Patient 1 demonstrated a M2 predominant, destructive thyroiditis 
with moderate T-cell and sparse B-lymphocytic infiltrates. Many M2 and 
thyroid gland cells were positive for PD-L1 and few T-lymphocytes for 
PD-1. The thyroid of patient 5 was markedly atrophic with prominent 
lymphocytic inflammation accompanied by few M2. B- lymphocytes 
represented over 50 % of inflammatory cells. Between 5% and 9% of 
lymphocytes were positive for PD-1. PD-L1 was negative. CD25 positive 
Table 3 
Autopsy findings and immune related adverse events (irAE).  
ID Residual Tumor Hypophysitis Adrenalitis ACTH Cortisol Other irAEs 
1 No Yes Yes 15 ng/l 2 nmol/l Thyroiditis, myocarditis, pneumonitis, hepatitis 
2 Liver and bone Yes Yes n.a. n.a. No 
3 No Yes Yes 15 ng/l 72 nmol/l Colitis 
4 Extensive Yes n.a 1200 ng/l 1300 nmol/l Colitis 
5 Brain Yes Yes n.a. n.a. Thyroiditis, hepatitis 
6 Extensive Yes n.a. n.a. n.a. No 
n.a. not available. 
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Fig. 1. a A-L: Adrenal gland (patient 1) with pronounced inflammation and mild fibrosis (A: Hematoxylin and eosin; B: Elastica van Gieson). Overview with 
moderate CD3 positive lymphocytes (C) and extensive CD163 positive macrophages type 2 (D). F and J: high-power views of C and D. E-J: Same areas with many CD4 
positive cells, mostly representing macrophages with co-expression of CD68 (I) and CD163 (J). T-lymphocytic infiltrates with equal distribution of CD4 (E) and CD8 
(G). Single B-lymphocytes with positivity for CD 20 (encircled, H). Only rare CD25 positive T-cells (L; inset: positive control). PDL-1 positive macrophages 
(arrowhead) and weak membranous positivity in parenchymal cells (arrow, K). b A-L: Pituitary gland (patient 2) with pronounced inflammation and moderate 
fibrosis (A: Hematoxylin and eosin; B: Elastica van Gieson). Overview with moderate CD3 positive lymphocytes (C) and extensive CD163 positive macrophages type 2 
(D). F and J: high-power views of C and D. E-L: Same areas with many CD4 positive cells mostly representing macrophages with co-expression of CD68 (I) and CD163 
(J). T-lymphocytic infiltrates with slight CD4 (E) predominance over CD8 (G). Absence of B-lymphocytes (inset with positive control; H). Extensive positivity for PDL- 
1 with predominance of anterior pituitary gland cells (L) over macrophages (K). c A-D: Patient 4 with acute necrosis of the anterior pituitary gland and myelo-
peroxidase positive granulocytic (D) and CD 68 positive (B) macrophage rich inflammation and few T-lymphocytes (C). E-J: Patient 3 with pronounced atrophy and 
fibrosis of the pituitary gland, especially in the anterior gland (E: Hematoxylin and eosin; G: Elastica van Gieson). F and H close up views of E and G. Moderate CD3 
positive (I) T-lymphocytic infiltration and few CD20 positive (J) lymphocytes. 
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cells were sparse or absent in both glands (Table 4; Fig. 2a) 
3.2.5. Liver of patient 1 and 2 
In the liver of both patients, over 50 % of inflammatory cells were M2 
accompanied by a moderate T-cell infiltration. In patient 1, CD4, and in 
patient 2, CD8 positive T-lymphocytes predominated. Only single cells 
were positive for CD20 or CD25. M2 were positive for PD-L1 in over 9% 
in patient 2 and less than 1% in patient 1 whereas liver cells were 
negative in both patients. Macrophages and liver cells were PD-1 
negative Fig. 3b). 
3.2.6. Lungs of patient 1 
Focal M2- rich interstitial inflammation was observed with moderate 
CD4- and very few CD8-postive infiltrates. CD25 positive T-cells and 
Table 4 
Immunohistochemical analysis of inflammation, PD1 and PDL-1 expression.  
Patient Organ CD3* CD4* CD8* CD25* CD20* CD68* CD163* PD1** PD-L1 P/I*** 
1 Pit. Gl. 2+ 2+ 2+ 1+ 2+ 3+ 3+ – 3+/1+
1 Adr. 3+ 2+ 2+ – – 4+ 4+ – 1+/1+
1 Thyroid 3+ 2+ 2+ 1+ 1+ 4+ 4+ 2+ 3+/2+
1 Lung 3+ 3+ 1+ – 1+ 4+ 4+ – -/3+
1 Heart 3+ 2+ 2+ – – 3+ 3+ – -/1+
1 Liver 3+ 3+ 1+ – – 4+ 4+ – -/1+
2 Pit. gl. 3+ 3+ 2+ – – 3+ 3+ – 3+/1+
2 Adr. 3+ 2+ 3+ – 1+ 4+ 4+ – 2+/3+
2 Liver 3+ 2+ 3+ – – 4+ 4+ – -/4+
3 Pit. gl. 3+ 3+ 2+ – 1+ 4+ 4+ 2+ 1+/- 
3 Adr. l.s. 3+ 3+ 2+ – 1+ 4+ 4+ – -/- 
3 Adr. r.s. 3+ 3+ 2+ – 1+ 4+ 4+ – -/1+
3 Colon 2+ 2+ 2+ – 1+ 4+ 4+ 1+ -/3++
4 Pit. gl. 1+ 1+ 1+ n.a. n.a. 4+ n.a. n.a. n.a. 
5 Pit. gl. 2+ 2+ 2+ – 2+ 3+ 3+ – 1+/1+
5 Adr. 2+ 2+ 2+ – – 4+ 4+ – -/- 
5 Thyroid 3+ 3+ 3+ – 4+ 2+ 2+ 3+ -/- 
6 Pit. gl. 2+ 2+ 2+ – 3+ 3+ 3+ – 3+/1+
Pit. gl., Pituitary gland; Adr., Adrenal gland; l.s, left side; r.s., right side; n.a., not available; 
* Semi-quantitative scoring scale for inflammatory cells: - absence or positivity in <1% of inflammatory cells ; 1+ positivity in 1–5 %, 2+ positivity in 6–25 %, 3+
positivity in 26–50 % and 4+ positivity in over 50 % of inflammatory cells. 
** Semi-quantitative scoring scale for PD-1: - absence, 1+ positivity in <1%, 2+ positivity in 1% and 4%, 3+++ positivity in 5 %–10 % of inflammatory cells. 
*** Semi-quantitative scoring scale for PD-L1 in parenchymal (P) and inflammatory (I) cells: - absence, 1+ positivity in <1%, 2+ positivity in 1 %–4 %, 3+ positivity 
in 5 %–50 % of parenchymal (P) cells. For inflammatory cells (I) 3+ corresponds to a positivity in 5 %–9 % and 4+ to a positivity over 9% of inflammatory cells. 
Fig. 2. a Comparison of thyroid gland of patient 1 (A-F) and patient 5 (G-L): Patient 1 with M2 macrophage rich lymphocytic thyroiditis. Moderate numbers of CD3 
positive T-cells (B), few numbers of CD25 positive T-regs (inset high-power view; D) or CD20 positive B-cells (C). In contrast, patient 5 with atrophic heavy lym-
phocytic infiltrated gland, predominated by B (I) over T-cells (H). Atrophic gland illustrated with positivity for TTF-1 (J). Patient 1 with numerous plasma mem-
branous PD-L1 positive thyroid gland cells (E), whereas patient 5 has weak diffuse cytoplasmic staining in thyroid gland cells which was considered negative and 
negativity in macrophages (K). Glands of both patients with PD-1 positive T-lymphocyte (F, L). b Colon biopsy of patient 2: Minor hyperplastic mucosa with 
elongated crypts, focal moderate active inflammation and apoptosis (A: hematoxylin-eosin). Inflammation subepithelial pronounced M2 macrophage rich with 
positivity for CD163 (E). Moderate lymphocytic infiltration with CD3 positive partly intraepithelial T-cells (B) and few B-cells (D). Much more CD4 positive cells (C) 
compared to CD3 partly representing macrophages with co-expression of CD 163. Negativity for T-regs (F) in the inflamed area. 
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CD20 positive B-cells were rare. M2 were moderately positive for PD-L1 
and PD-1 negative. Parenchymal cells were PD-1 and PD-L1 negative 
(Fig. 3a). 
3.2.7. Myocardium of patient 1 
Moderate M2 and CD4 and CD8 positive lymphocytes were found 
with only rare B-lymphocytes and absence of T-regs. Less than 1% of M2 
were positive for PD-L1 whereas parenchymal cells were negative. M2 
and parenchymal cells were PD1 negative (Fig. 3c). 
3.2.8. In vivo colon biopsy of patient 3 
The biopsy demonstrated mildly hyperplastic mucosa with elongated 
crypts, focal moderate active inflammation and increased apoptosis. The 
cellular infiltrate was mostly subepithelial and consisted mainly of M2 
coexpressing CD68 and CD163. There was a moderate lymphocytic 
infiltration with CD3 positive partly intraepithelial T-cells and no 
obvious difference in CD4 and CD8 expression. Only few CD20 positive 
B-lymphocytes were present with single cells positive for CD25. PD-L1 
was moderately focal positive in M2 and negative in epithelial cells. 
PD-1 was negative (Fig. 2b, Table 4). 
4. Discussion 
Our autopsy study investigates 6 patients with the dreaded adverse 
event of immune therapy related hypophysitis. All patients received 
CTLA-4 antibody therapy and four received additional immunemodu-
latory therapy against PD-1 at outset in combination with Ipilimumab or 
after treatment was modified. Patients 5 and 6 differ from the others, 
because ICI therapy was stopped 40 or 17 weeks before death. In addi-
tion, these 2 patients received BRAF and MEK inhibitors or cytotoxic 
chemotherapy (Table 2). 
All patients treated with ICI alone, with the exception of patient 4, 
demonstrated mild to moderate T-lymphocytic infiltration in irAE 
involved organs with an equal distribution of CD4 and CD8 or slightly 
increased CD4-lymphocytes. Only rare B-lymphocytes were observed 
(Fig. 1). In contrast, patients in whom ICI therapy had been suspended 
and switched to tyrosine kinase inhibitors and chemotherapy, developed 
significant B-lymphocytic infiltrates. These observations indicate that 
Fig. 3. a–c Inflammation of the lung (3a), liver (3b) and heart (3c) of patient 1 with illustration of the cellular components. Moderate T-cell predominant lym-
phocytic infiltrations with positivity for CD3 (C) and negativity or single cell positivity for B-lymphocytes (inset with positive control; B) in the lung septum, pa-
renchyma of the liver and heart. T-lymphocytes mainly with positivity for CD4 (D) and rare positivity for CD8 (E). Many CD4 positive cells (D) have spindle cell 
morphology and co-expression of CD163 (F) representing M2 macrophages. PD-L1 positivity in macrophages with negativity in lung, liver and myocard cells (G). In 
the lung positive alveolar macrophages (arrow) and septal macrophages with spindle cell morphology (arrowhead). 
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PD-1, respectively CTLA-4 inhibiting T cell activation is partially 
responsible for irAEs in patients treated with ICIs. Surprisingly, the 
dominant inflammatory population was not T-cell, but M2 macrophages 
with positivity for CD68 and CD163. With the exception of the thyroid 
gland in patient 5, all involved organs demonstrated M2 rich inflam-
mation. Of note, CD25 positive T-regs were sparse or absent in the or-
gans of all patients with the exception of the thyroid and pituitary gland 
in patient 1 (Fig. 1 and 2). The histological features are reminiscent of 
the macrophage-activated syndrome (MAS) seen in systemic juvenile 
arthritis. This life-threatening syndrome of hyperinflammation and 
progressive immune-mediated organ damage is due to an over- 
stimulated but ineffective immune response (Daver et al., 2017). How-
ever, the syndrome is based on clinical criteria, the pathophysiology is 
still unclear with different triggers such as infections, malignancies, 
autoimmune disorders and drugs. Interestingly, the syndrome has also 
been also described in a patient receiving Pembrolizumab (Al-Samkari 
et al., 2019; Hantel et al., 2018; Kalmuk et al., 2020; Sadaat and Jang, 
2018). 
PD-1, PD-L1 and CTLA-4 expression is found not only in lymphocytes 
but also in monocytes/macrophages (Gordon et al., 2017; Pistillo et al., 
2003; Wang et al., 2002). Whereas the function of PD-1, PD-L1 and 
CTLA-4 inhibiting T cell activation is understood, there is no consensus 
about the function of PD-1, PD-L1 and CTLA-4 in macrophages. How-
ever, studies increasingly show an inhibitory function on the immune 
system. 
In monocyte/T-cell co cultures, it was shown that Ipilimumab en-
gages a subgroup of non-classical FcγRIIIA (CD16)-expressing mono-
cytes and lyses T-regs via antibody dependent cell-mediated cytotoxicity 
(ADCC). Patients responding to Ipilimumab displayed significantly 
higher baseline peripheral non- classical monocyte counts compared 
with non-responder patients and had fewer T-regs (Romano et al., 
2015). The protective function of T-regs against auto-immune disease in 
mice and human is well known (Buckner, 2010). Our observations with 
heavy M2 inflammation and relative reduction of T-regs support the 
hypothesis that irAEs are at least partly due to Treg deficiency. Impor-
tantly, the lack of T-regs may contribute to a favorable response to ICI 
therapy (Romano et al., 2015). However, CTLA-4 expression is also well 
known in T-regs, as well as their role in suppression, T cell receptor 
hyposignaling and anergy (Tai et al., 2012). One could therefore hy-
pothesize a direct CTLA-4 antibody dependent, cell-mediated cytotox-
icity against T-regs accompanied by a secondary M2 rich type II immune 
reaction. Since T-regs are sparse or absent after cessation of CTLA-4 
antibody therapy, the impairment seems irreversible or perhaps other 
mechanisms are involved. 
Another study demonstrated that in sepsis patients, peritoneal 
macrophages expressed high levels of PD-1 and were anergic with lower 
bactericidal capacity. In addition, PD-1 -/- mice with sepsis had lower 
mortality and a decreased bacterial burden compared with wild-type 
mice with sepsis (Huang et al., 2009). Studies with tumor associated 
macrophages (TAM) showed that PD-1 positive TAM correlate with 
decreased phagocytic potency against tumor cells. In addition, blockade 
of PD-1 or PD-L1 in vivo increases macrophage phagocytosis and re-
duces tumor growth. TAM are mainly M2, have higher levels of CD4 and 
are associated with tumor progression (Gordon et al., 2017; Sica et al., 
2006). Our observation of minimal or absent PD-1 expression in CD4 
positive macrophages type 2 suggests that therapy with anti-PD-1 im-
pairs PD-1 expression and function in macrophages and might therefore 
be responsible for the uncontrolled immune response. 
There is increasing evidence that macrophages lead to inflammation 
and autoimmunity due to an increased pro-inflammatory M1/anti-in-
flammatory M2 ratio (Smith et al., 2009; Zhu et al., 2014). Traditionally, 
there has been a clear dichotomy between pro-inflammatory (M1) and 
immunosuppressive (M2) macrophages (Fang et al., 2018). However, 
evidence is mounting that the situation is far more complex. Currently, 
three subsets of M2 (M2a, M2b, M2c) macrophages are recognized. M2b 
macrophages also exhibit a pro-inflammatory effect with cytokine 
production and Th2 activation as well as participation in type II and 
allergen reactions (Martinez and Gordon, 2014; Varin et al., 2010). 
However, in ICI therapy related inflammation there is a clear-cut pre-
dominance of a M2 destructive process, indicating a type II reaction 
accompanying the T-cell mediated process. 
In the pituitary, CTLA-4 expression responsible for type II reaction 
has been reported in patients treated with anti-CTLA-4 antibody Ipili-
mumab (Caturegli et al., 2016; Iwama et al., 2014). We performed 
immunohistochemistry for CTLA-4 with the same antibody in all organs 
involved with irAEs. However, partly due to nuclear and non-specific 
immune-reactions, we were not able to evaluate the staining. Interest-
ingly, in all cases we observed moderate to strong expression of PD-L1 in 
the pituitary (Table 4; Fig. 1b L). Since our patients received anti- PD-1 
therapy, a direct cytotoxic reaction against PD-L1 is unlikely. However, 
this observation could be relevant for patients treated with anti-PD-L1. 
PD-1 is expressed in hematopoietic cells (Sun et al., 2018). A reaction 
between PD-1 antibody and PD-1 positive M2 macrophages could ac-
count for suspected type II irAEs in patients treated with PD-1 antibody. 
The observed minimal or absent PD-1 expression despite heavy M2 
inflammation could sustain this scenario. However, PD-1 expression was 
minimal or absent, even in patients 5 and 6, who received no anti-PD-1 
therapy, 17 respectively 40 weeks before death. This raises the question 
whether PD-1 expression in macrophages is impaired for other reasons. 
PD-L1 expression was observed in M2 in several different organs. 
(Table 4; Fig. 1a, 1b, 2a, 3a-c). A study reported that PD-L1 expression 
does not inhibit T-cell response but protects macrophages from 
destruction by T-cells, unlike PD-L1 expression on tumor cells (Sica 
et al., 2006). This mechanism could support our observed accumulation 
of M2. 
Our findings with concurrent alterations in several different organs 
illustrate that irAEs represent a systemic disease in patients undergoing 
ICI therapy. Adrenalitis was observed in all four patients with hypo-
physitis. In two patients with available ACTH and cortisol levels, the 
measurements were low. A single case showed acute pituitary gland 
necrosis with increased serum ACTH and cortisol levels (Table 2). 
Furthermore, two patients had hepatitis and thyroiditis, another 
pneumonitis and one myocarditis (Table 3). Of clinical importance is our 
observation of the dual impairment of the pituitary and adrenal gland in 
patients undergoing ICI therapy, which was responsible for life threat-
ing, low cortisol levels. 
The strength of our study is the availability of autopsy tissue from 
multiple organs of six patients. The weakness of the study is that patients 
received different medications. Since some autopsies were analyzed in 
more detail retrospectively, not all adrenal glands were available. 
5. Conclusion 
Side effects caused by immunotherapy are a systemic disease. T-cell 
activation is only one part of the pathogenesis. Progressive M2 immune- 
mediated organ damage and depletion of T-regs also play an important 
role. 
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